ACVR1 and fibrodysplasia ossificans progressiva: Recent data from a novel ACVR1 inhibitor, BLU-782, indicate that blocking ACVR1 in the early stages of FOP alleviates the fibroproliferative response and reduces the bone volume of HO (Davis et al, 2024).